If you are considering psychedelic-assisted treatment in Ireland — for yourself or for someone close to you — the map in July 2026 shows one publicly funded route, a private market that barely exists yet, and a research scene stronger than the country's size suggests. This guide covers who qualifies for each real route, how to start, what it costs, and what to realistically expect; you can begin orienting yourself with our eligibility check.
TL;DR Spravato (esketamine) has been reimbursed by the HSE since January 2022 for adults with treatment-resistant depression, in combination with an oral antidepressant — but only a psychiatrist can initiate it, and delivery is concentrated in a limited number of specialist psychiatric services. The private route is thin: as of July 2026, no operating private ketamine-assisted psychotherapy programme in Ireland could be verified. Psilocybin and MDMA are research-only. The live opportunity is the Phase 3 CYB003 trial (a psilocin analog for major depression), recruiting at Tallaght in Dublin and La Nua in Galway; no Irish MDMA trial exists.
At a glance
| Route | Substance | Status in Ireland | Who qualifies | Cost |
|---|---|---|---|---|
| Reimbursed esketamine | Esketamine (Spravato) | HSE-reimbursed since January 2022; limited sites | Adults with treatment-resistant depression, psychiatrist-initiated, in combination with an SSRI or SNRI | Covered via HSE specialist psychiatric services |
| Private ketamine-assisted psychotherapy | Ketamine (off-label) | Not running: no operating programme verified as of July 2026 | — | — |
| Psilocybin / psilocin analogs | Psilocybin, CYB003 | Research only; Phase 3 CYB003 recruiting in Dublin and Galway | Study-specific criteria (major depressive disorder) | Free in trials |
| MDMA | MDMA | Research only in principle; no Irish MDMA trial exists | — | — |
| Clinical trials | Psilocybin, ketamine, 5-MeO-DMT | 13 Ireland-linked trials tracked, 2 active | Study-specific criteria | Free |
Full coverage details: Is Spravato reimbursed in Ireland?
Esketamine (Spravato): reimbursed, psychiatrist-initiated, few doors
Ireland approved reimbursement of esketamine nasal spray in January 2022, following confidential price negotiations between the HSE and the manufacturer after the national health-technology assessment (NCPE HTA ID 19055). The reimbursed indication is treatment-resistant major depressive disorder in adults — a moderate-to-severe episode that has not responded to adequate trials of antidepressants — used in combination with an SSRI or SNRI, per the EU label (EMA product information).
Two features define the Irish route in practice:
- The decision to prescribe sits with a psychiatrist. Your GP cannot start esketamine; their role is to refer you into psychiatric care with a documented treatment history. Once prescribed, you self-administer the spray under the direct supervision of a healthcare professional, followed by an observation period.
- Delivery is concentrated, not universal. Reimbursement is a funding decision, not a capacity decision. Uptake has been limited and clustered in specialist psychiatric services, because supervised administration demands space, staff and a monitoring routine (Blossom: Ireland country report). Expect your psychiatrist to know whether a programme runs in your catchment area; in some regions the candid answer will be "not yet". Galway has been a visible growth point, with HSE material showing esketamine services presented for treatment-resistant depression in the west.
How to start. Bring your psychiatrist — or ask your GP for a referral into secondary care — a written treatment history: every antidepressant tried in the current episode, with substance, dose, duration and outcome, plus any augmentation and psychotherapy. That record is what turns "we could consider esketamine" into a scheduled assessment. For patients who qualify through public services, treatment is covered; for how Ireland compares with its neighbours, see our Europe-wide reimbursement map.
Private ketamine-assisted psychotherapy: not yet open
Ireland does not have the private ketamine-clinic market of the UK or Germany. As of July 2026, we could not verify any private clinic in Ireland with an operating ketamine-assisted psychotherapy programme — no running programme, no published prices, no public screening criteria. The honest description of the Irish private route is that it does not exist yet.
What this means practically: if you are researching Irish KAP today, there is no programme to book. If one does open, ask what it will include (medical screening, preparation, supervised administration, integration), what it will cost in writing, and which physicians will run the medical side. Treat any Irish offer of ketamine therapy that is available immediately, without psychiatric screening, with caution — and check what is listed near you by browsing providers in Ireland.
Psilocybin: research only — with a real Irish research scene
Psilocybin and psilocin are Schedule 1 controlled substances in Ireland, and psilocin-containing mushrooms have been expressly controlled since 2006; lawful use is confined to licensed research (Blossom: Ireland country report). No compassionate-access or special-access route exists. The research scene, however, is one of the more credible in Europe for a country of five million:
- The live opportunity in August 2026 is the Phase 3 CYB003 (EMBRACE) trial — a deuterated psilocin analog studied as an adjunct in major depressive disorder — recruiting at Sheaf House, Tallaght Adult Mental Health Service in Dublin and La Nua Day Hospital Mental Health Centre in Galway (NCT06793397).
- The track record runs through the Trinity College Dublin and Tallaght University Hospital Psychedelic Research Group: Tallaght was an Irish site in the COMP360 psilocybin Phase 2b trial in treatment-resistant depression, published in the New England Journal of Medicine in 2022, and Ireland participates in the follow-on Phase 3 COMP360 programme (active, no longer enrolling).
- The pipeline is broadening: Trinity lists projects including POSITRON, a pilot psilocybin feasibility study for cocaine use disorder, and Dublin-headquartered GH Research published Phase 2b results for its 5-MeO-DMT compound GH001 (mebufotenin) in treatment-resistant depression in 2026.
If your situation fits the CYB003 trial's profile — adults with major depressive disorder — ask your psychiatrist or GP about a referral to the Tallaght or Galway study team. Outside a trial, anyone selling psilocybin therapy in Ireland today is committing an offence.
MDMA: no route, not even a trial
MDMA is a Schedule 1 controlled substance in Ireland with no medical-access route — and unlike psilocybin, there is no Irish research foothold either. As of July 2026, no MDMA trial with an Irish site is recruiting or has been registered: a ClinicalTrials.gov search for MDMA studies in Ireland returns none, and Blossom's Ireland tracker lists no MDMA study among the country's thirteen linked trials. If MDMA-assisted therapy matters to you, the realistic options are watching the registries or considering trial sites elsewhere in Europe — our trials guide explains how to search and what participation involves. Anyone offering MDMA therapy commercially in Ireland today is operating illegally.
Clinical trials in Ireland
Blossom currently tracks 13 psychedelic clinical trials connected to Ireland, 2 of them active, with ketamine and psilocybin the most-studied compounds and depression the dominant topic (Blossom: Ireland country report). Beyond the psilocybin work above, Irish ketamine research is mature enough to produce negative findings worth knowing: the St Patrick's-linked KARMA-Dep 2 trial reported in October 2025 that serial ketamine infusions added no benefit in hospitalised depression — a result that should temper expectations about ketamine as a cure-all. Dublin and Tallaght form the main hub, and Galway has become a genuine second centre. Participation is free and legal, but screening is strict and enrolment is never guaranteed, and trial screening can run in parallel with a public esketamine referral. See the trials guide for how phases, placebo and consent work, and search ClinicalTrials.gov for current Irish listings.
What to expect in treatment
Medically reviewed by Dr. Amy Reichelt, PhD, 31 July 2026 — this section and the risks section below.
These routes share a shape — medical screening, supervised administration, structured follow-up — but they are not interchangeable: the indication, the schedule, the staffing and the strength of the evidence all differ depending on whether you are prescribed Spravato (esketamine), given ketamine, or entering a legal psychedelic-assisted therapy route, where your country has one. What every route has in common is where it starts. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.
On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate, sedation, dissociation, breathing and overall recovery. Dissociation, dizziness, sedation, nausea and a temporary rise in blood pressure are common — though they do not occur in everyone — and settle as the drug clears. You must not drive, operate machinery or undertake anything hazardous until the following day, after a night's sleep, so arrange transport home. Induction is typically more frequent at first and then tapers based on measured response. Under the European label, Spravato for treatment-resistant depression is taken alongside a continuing oral SSRI or SNRI antidepressant.
A ketamine infusion for depression is an off-label use of the drug. It is usually given intravenously over about 40 minutes, with vital-sign and psychological monitoring and a recovery period afterwards. Some services offer ketamine-assisted psychotherapy (KAP), which wraps the dosing in preparation and integration sessions with a therapist; others provide ketamine as a medical antidepressant treatment with no psychotherapy component at all, which is worth establishing before you book. Where a legal psychedelic-assisted therapy route exists — and what that route is depends on the country: a clinical trial in most, a regulated programme or compassionate-use scheme in a few — dosing days are long and closely supervised by trained clinical staff, and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up reduce risk but cannot eliminate it, and psychotherapy or integration may help you make sense of what the treatment brings up and apply it afterwards.
Risks and who should not start
These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:
- Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease. This is a contraindication for Spravato, because of the temporary rise in blood pressure; the other treatments carry their own cardiovascular assessment.
- A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
- Pregnancy or breastfeeding.
- Current uncontrolled substance use, a history of ketamine misuse, or a high risk of compulsive use — any of these may make treatment inappropriate or require specialist assessment.
A responsible provider screens for all of these before the first dose. Careful screening, monitoring and follow-up reduce risk; they do not remove it. If a clinic is willing to treat you without that assessment, treat it as a warning sign — see our clinic-choice guide. To see who is listed near you, browse providers in Ireland.
Reviewer's note. Ketamine, Spravato (esketamine) and psilocybin-assisted therapies share common elements such as screening, supervision and follow-up, but they should not be presented as interchangeable. Each has distinct indications, contraindications, monitoring requirements and levels of evidence. Spravato follows a regulated treatment pathway, while IV ketamine is generally used off-label and psilocybin therapies remain largely investigational. Importantly, careful screening and clinical monitoring reduce risk but do not eliminate it.
— Dr. Amy Reichelt, PhD, neuroscientist, chartered psychologist and psychotherapist, PsyAccess review board
Frequently asked questions
Is Spravato free in Ireland?
For patients who qualify through public specialist psychiatric services, yes — the HSE has reimbursed it since January 2022. The gatekeepers are clinical: a psychiatrist must initiate treatment, and a supervised-administration site must have capacity in your area.
Can my GP prescribe esketamine or refer me directly to a session?
No. The decision to prescribe sits with a psychiatrist. Your GP's role — and it is an important one — is to refer you into psychiatric care with a documented treatment history that makes the assessment fast.
Is there anywhere in Ireland I can book ketamine-assisted psychotherapy today?
Not as of July 2026 — we could not verify any operating private KAP programme in Ireland. Some Irish patients have historically looked at services in Northern Ireland or Great Britain; if you do, apply the same screening-and-written-costs checklist.
How do I join the Irish psilocybin-analog trial?
The Phase 3 CYB003 (EMBRACE) trial for major depressive disorder is recruiting at Tallaght Adult Mental Health Service (Sheaf House) in Dublin and La Nua Day Hospital in Galway. Ask your psychiatrist or GP about a referral to the study team, and read the entry criteria on the registry first (NCT06793397).
Can I get MDMA therapy in Ireland?
No — not in care, and currently not even in research. No Irish MDMA trial exists as of July 2026. Watch the registries or consider trial sites elsewhere in Europe.
How long will I wait for each route?
Public esketamine: the psychiatric referral plus whether a programme runs in your region — weeks to months, and honest regional gaps exist. Private KAP: no verified Irish programme exists yet, so there is no timeline to plan around. Trials: screening typically takes weeks, with no guarantee of enrolment, and can run in parallel with a public referral.
Sources
- NCPE — Esketamine (Spravato) HTA ID 19055
- Irish Medical Times: Spravato approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder (2022)
- Blossom: Ireland country report
- Blossom: Medical access in Ireland
- Psychedelic Alpha: Worldwide psychedelic laws tracker
- EMA: Spravato (esketamine) EPAR
- ClinicalTrials.gov: NCT06793397 — CYB003 (EMBRACE) Phase 3 in major depressive disorder (recruiting; Dublin and Galway sites)
- Trinity College Dublin — Psychedelic Research Group (Trinity and Tallaght)
- Trinity College Dublin: Promising results from psilocybin therapy trial for treatment-resistant depression (COMP360 Phase 2b, Tallaght site)
- NEJM: Single-dose psilocybin for a treatment-resistant episode of major depression (COMP360 Phase 2b)
- PubMed: KARMA-Dep 2 — adjunctive serial ketamine in hospitalised depression (2025)
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and reimbursement rules change; always verify current requirements with the HSE, your psychiatrist, or a licensed clinician who knows your history. If you are in crisis, contact emergency services (112 or 999) or the Samaritans on 116 123 immediately.
This guide awaits review by a licensed medical professional.